Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era

被引:0
|
作者
Armendariz, Beatriz G. [1 ]
Chakravarthy, Usha [2 ]
机构
[1] Roche Innovat Ctr Basel, Roche Pharm Res & Early Dev, 124 Grenzacherstr, CH-4058 Basel, Switzerland
[2] Queens Univ Belfast, Belfast, North Ireland
来源
关键词
COHERENCE TOMOGRAPHY ANGIOGRAPHY; PIGMENT EPITHELIAL DETACHMENT; GROWTH-FACTOR THERAPY; SUBRETINAL FIBROSIS; CHOROIDAL NEOVASCULARIZATION; FIBROTIC SCAR; VISUAL-ACUITY; RISK-FACTORS; RANIBIZUMAB; EYES;
D O I
10.1038/s41433-024-03308-6
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
The natural history of neovascular age-related macular degeneration (nAMD) leads to scarring and loss of vision. Since the advent of anti-VEGF therapies, which are very effective for controlling exudation, large disciform scars are rarely encountered in the clinic. However long term studies show that smaller and less severe fibrotic scars are not uncommon and develop over time despite optimal treatment. This means that additional mechanisms of action may be required to completely address this condition. To permit new treatments, a proper understanding of the clinical impact of fibrosis is required. This review is focused on clinical aspects of fibrosis and summarises recent data on biomarkers, prevalence, causes, consequences, and therapies, highlighting the most important and urgent topics to tackle in order to advance in the treatment of fibrosis.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Neovascular age-related macular degeneration and anti-VEGF nonresponders
    Sheybani, Arsham
    Almony, Arghavan
    Blinder, Kevin J.
    Shah, Gaurav K.
    [J]. EXPERT REVIEW OF OPHTHALMOLOGY, 2010, 5 (01) : 35 - 41
  • [2] ANTI-VEGF TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN AUSTRALIA
    Finger, Robert
    Fotis, Kathy
    Cummins, Rob
    Heraghty, Julie
    Guymer, Robyn
    [J]. CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2014, 42 : 14 - 14
  • [3] Development of Subretinal Fibrosis After Anti-VEGF Treatment in Neovascular Age-Related Macular Degeneration
    Hwang, John C.
    Del Priore, Lucian V.
    Freund, K. Bailey
    Chang, Stanley
    Iranmanesh, Reza
    [J]. OPHTHALMIC SURGERY LASERS & IMAGING, 2011, 42 (01) : 6 - 11
  • [4] Switching intravitreal anti-VEGF treatment in neovascular age-related macular degeneration
    Kucukerdonmez, Cem
    Gelisken, Faik
    Yoeruek, Efdal
    Bartz-Schmidt, Karl Ulrich
    Leitritz, Martin Alexander
    [J]. EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2015, 25 (01) : 51 - 56
  • [6] Adjuvant radiotherapy during anti-VEGF in neovascular age-related macular degeneration
    Rating, P.
    Freimuth, M. -A.
    Stuschke, M.
    Bornfeld, N.
    [J]. OPHTHALMOLOGE, 2017, 114 (04): : 370 - 374
  • [7] Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration
    Finger, Robert P.
    Wickremasinghe, Sanjeewa S.
    Baird, Paul N.
    Guymer, Robyn H.
    [J]. SURVEY OF OPHTHALMOLOGY, 2014, 59 (01) : 1 - 18
  • [8] Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review
    Yang, Shiqi
    Zhao, Jingke
    Sun, Xiaodong
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 1857 - 1867
  • [9] Anti-VEGF and Other Novel Therapies for Neovascular Age-Related Macular Degeneration: An Update
    Mariacristina Parravano
    Eliana Costanzo
    Giulia Scondotto
    Gianluca Trifirò
    Gianni Virgili
    [J]. BioDrugs, 2021, 35 : 673 - 692
  • [10] Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration
    Wykoff, Charles C.
    Clark, W. Lloyd
    Nielsen, Jared S.
    Brill, Joel V.
    Greene, Laurence S.
    Heggen, Cherilyn L.
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (02): : S3 - S15